



LAMAR UNIVERSITY
MANUAL OF ADMINISTRATIVE POLICIES AND PROCEDURES

SECTION: Academic Affairs
AREA: ORSPA

MAPP 02.07.06

Institutional Biosafety Committee

I. POLICY

- A. At Lamar University, our commitment to fostering a culture of excellence in research, innovation, and academic pursuits is paramount. To ensure the integrity, quality, and effectiveness of our research endeavors, it is essential to define terms, establish responsible parties, and provide guidance.

II. P

IV. DEFINITIONS

- A. Biohazardous Materials, Agents, and Toxins. Infectious biological or synthetic agents, biologically derived materials and toxins that present a risk or potential risk to the health of humans, animals, or plants either directly through exposure or infection or indirectly through damage to the environment. Categories of potentially infectious biological materials include:
1. Human, animal, and plant pathogens (bacteria, parasites, fungi, viruses, prions).
 2. All human and nonhuman primate blood, blood products, tissues, and certain body fluids (use of human blood and body fluid for clinical diagnostic and treatment purposes is excluded).
 3. Cultured cells and potentially infectious agents these cells may contain.
 4. Infected animals and animal tissues.
- B. Chief Research Officer. An individual ultimately responsible for the oversight of funded research and sponsored programs at Lamar University. At Lamar University, the Chief Research Officer is the Associate Provost for Research. The Chief Research Officer may designate an appropriate official to act on their behalf.

2. Protocols that include the possession and/or use of recombinant or synthetic nucleic acid molecules and biohazardous materials, agents, and toxins will be reviewed for compliance with NIH Guidelines, the BMBL, and Select Agents and Toxins regulations. As part of the review process, the IBC will perform the following:
 5. Conduct an independent assessment of the containment levels (BSL-1 to BSL-3), as required by the NIH Guidelines or the BMBL.
 6. Ensure adherence with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines for recombinant or synthetic nucleic acid molecules research and the select agents and toxins regulations.
 7. Submit member rosters (completed by RSC) including members' biographical sketches to NIH/OBA.
 8. Obtain specific review, registration and/or approval from NIH/OBA for research that fall under Sections III-A, III-B, III-C and Appendix M.
- D. Office of Research and Sponsored Programs Administration. The Office of Research and Sponsored Programs Administration shall be represented by the Research Compliance Officer as appointed by the Chief Research Officer. This individual has the following responsibilities:
 1. Maintaining current and accurate files on every researcher involved in biological research.
 2. Requesting updated disclosures and approvals from researchers at the time of funding.
 3. Developing approved management plans when applicable.

3. Instruct, train, and supervise research personnel in (1) practices and techniques required to ensure safety, and (2) procedures for dealing with spills or potential exposures to the agents described in the research.
4. Ensure the integrity of the physical containment (e.g., biological safety cabinets) and the biological containment (e.g., purity and genotypic and phenotypic characteristics) and correct procedures or conditions that might result in release of or exposure to recombinant or synthetic nucleic acid molecules and/or biohazardous materials, agents or toxins.
5. Ensure all research personnel, including students, have the required training in the accepted procedures for laboratory practices and safety.
6. Obtain IBC approval prior to initiating or modifying any research involving use of recombinant or synthetic nucleic acid molecules and/or biohazardous materials, agents, and toxins. Although federal regulations allow exemptions for some types of recombinant or synthetic nucleic acid molecules use, the Principal Investigator must submit an application for all projects using recombinant or synthetic nucleic acid molecules and biohazardous

X. COMMITTEE MEETING

- A. Scheduling. IBC meetings are routinely held every six months, or as needed. Rescheduling may occur due to inability to achieve a quorum of members and non-scheduled meetings may be called by the IBC Chair to discuss matters that arise and require immediate resolution. The Research

XIV. APPROVAL

Dr. Brett Welch	11/08/2024
Interim Provost and Vice President for Academic Affairs	Date

Dr. Jaime Taylor	11/08/2024
Lamar University President	Date

POLICY LOG

Version	Date	Description of Changes
1	01/01/2011	Issued.
	08/01/2023	Last updated.